Why AngioDynamics Stock Popped, Then Dropped Today AngioDynamics' big Q4 earnings beat wasn't as impressive as it first seemed.
AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting AngioDynamics expects a $4 million-$6 million impact from tariffs. Still, it's "profitable," CEO Jim Clemmer says.
Get insights into the top gainers and losers of Monday's after-hours session. Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Traders are paying attention to the gapping stocks in Wednesday's session. In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance AngioDynamics raised its fiscal 2025 sales outlook to $285M-$288M and boosted its adjusted EBITDA forecast, expecting stronger Med Tech revenue growth.
These stocks are moving in today's pre-market session The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
AngioDynamics Stock Rockets On Upbeat Q3, Improved Full-Year Guidance – But Retail Sentiment Plummets The medical technology company now expects net sales to be $285 to $288 million for the fiscal year 2025, up from previously issued guidance of $282 to $288 million, owing to increased medical technology net sales.
3 Stocks Insiders Are Buying Heavily In October 2024, And Why Should investors add these stocks on their watchlist? Insider buys suggest so.
Why AngioDynamics Stock Is Crashing Today Investors didn't like the medical technology company's fiscal 2025 Q1 update.
